Objective: It was reported that the long acting insulin analogue glargine induces cell proliferation in a human osteosarcoma cell line, and therefore might induce or accelerate tumor growth. Induction of cell proliferation would be particularly relevant for insulin treatment of subjects with diabetes mellitus and the potential of bearing tumor cells, e.g. a history of a malignant disease.
iabetes mellitus is a chronically progressive disease (1) characterized by insulin deficiency that often requires exogenous insulin therapy. In order to more closely reproduce endogenous insulin dynamics several insulin molecules with structural modifications and either a shortened or prolonged action profile have been developed for clinical use (insulin analogues) (2) . Replacement of basal insulin in patients with diabetes mellitus is usually performed with either NPH insulin or a long acting insulin analogue like insulin glargine (3) . Two modifications of the human insulin structure at the C-terminus of the β-chain and at position 21 in the α-chain lead to the prolonged action profile of insulin glargine, because precipitation of the modified insulin molecule in the subcutaneous compartment delays absorption. However structural modifications of the amino acid sequence of the human insulin molecule might also induce changes of the biological effects of insulin. Insulin is an important regulator of glucose metabolism, protein metabolism, platelet activation and apoptosis as well as cell growth (4) (5) (6) (7) . Insulin initiates its effects via the insulin receptor but can also crossactivate the IGF-I receptor (8) . Based on in vitro studies it has been hypothesized that insulin glargine has an enhanced affinity to the IGF-I receptor and might be mitogenic (7) . Enhanced cell proliferation due to IGF-I receptor signalling would be particularly relevant for subjects with diabetes mellitus and the potential of bearing tumor cells, e.g. with a history of a malignant disease. After partial or total pancreatectomy patients with pancreatic cancer and diabetes mellitus often require insulin therapy. Pancreatic cancer is an aggressive disease with poor prognosis and a 5-year survival rate of less than 4%. When surgery is a therapeutic option, the median survival is 14-20 months and the 5-year survival increases to 20-25% (9) . After total pancreatectomy insulin therapy is mandatory while after partial pancreatic resection, depending on different surgical techniques and function of the remnant pancreas, up to ~50% of patients require an insulin therapy (10) . Therefore it is important to know whether insulin therapy in these patients requires differential considerations. We therefore posed the following questions: 1) Does insulin glargine induce cell proliferation in human pancreatic carcinoma cells? 2) Does insulin glargine affect the survival of patients after surgery for pancreatic carcinoma?
RESEARCH DESIGN AND METHODS.
Design. Human pancreatic cancer cells (Colo-357) were incubated for 72 hours in RPMI culture medium and treated either with insulin glargine (Sanofi-Aventis, Germany) or regular human insulin (Novo Nordisk, Denmark) at the following concentrations: 0, 0.01, 0.1, 1, 10 and 100nM. After static incubation Colo-357 cells were either analysed by flow cytometry or immunoblotting. Colo-357 cells were maintained in RPMI culture medium supplemented with 10% FBS, penicillin G (100 units/ml) and streptomycin (100µg/ml) at 37°C in a humidified air containing 5% CO 2 . Colo-357 cells are characterized by a high expression level of Insulin-Receptor-Substrate 2 (IRS 2), which is implicated in mitogenic signalling after activation of the insulin or IGF-I receptor. Prior reports showed that Colo-357 cells are insulin responsive cells (11) . In contrast to this and other studies we did not use serumfree medium for preconditioning / cell cycle synchronization of the cells because serum starvation does not represent a condition that occurs physiologically to cancer cells in vivo.
To corroborate the in vitro data 125 patients were retrospectively examined, in whom total or partial pancreatectomy had been performed due to pancreatic carcinoma. Patients were divided into three groups: 1) Control group without diabetes mellitus after pancreatectomy, 2) patients with diabetes mellitus and s. Changes at different concentrations of both insulin treatments were examined by ANOVA. P < 0.05 was considered to denote significant differences. Survival analysis (Kaplan-Meier) was performed as a 3-sample comparison with the software Statistica (version 6.1).
RESULTS.
Flow cytometric analysis. After 72 h static incubation of Colo-357 cells with either insulin glargine or regular human insulin, flow cytometric analysis was performed to determine proliferation and apoptosis (Fig.  1) . Colo-357 cells are characterized by a homogenous autofluorescence confirming that this cell type is an appropriate model for flow cytometric analysis (Fig. 1 A) . The fraction of PI-positive (non-viable) cells was always < 5 % (data not shown). Cells positive for Ki-67 or annexin V separated clearly from the unstained cell population ( Fig. 1 B and C) . The replication rate (percentage of Ki-67 positive cells) was 0.55 to 3.11%, the number of apoptotic cells (percentage of annexin V positive cells) was in the range of 0.94 to 4.84% (data not shown). There was no concentrationdependent change of cell proliferation after incubation with human insulin or insulin glargine (p=0.3 and p=0.4 by ANOVA, respectively; Fig. 1 D) . Furthermore there was no significant difference of cell replication after incubation with human insulin or insulin glargine at any of the individual concentrations tested (p=n.s.). Similarly there is no interaction between insulin concentrations and apoptosis for both insulins (p=0.9 for insulin glargine, p=0.2 for human insulin by ANOVA; Fig. 1 E) and there were no differences comparing individual concentrations (p=n.s.). Immunoblotting. To demonstrate that Colo-357 cells respond to exogenous insulin the phosphorylation level of the insulin receptor was measured by immunoblotting using a monoclonal phospho-specific antibody to the insulin receptor beta subunit. After incubation for 30 minutes the phosphorylation level of the insulin receptor was increased to a similar degree with regular human insulin or insulin glargine (Fig. 2 A and B) . Expression levels of insulin receptor, IGF-I receptor and IRS 2 were characterized in additional experiments by immunoblotting using specific rabbit polyclonal antibodies against the beta subunit of the IGF-I receptor and total IRS 2 and a monoclonal antibody against the insulin receptor beta subunit (Fig. 2 C) . The pattern of the expression levels of the IGF-I receptor and IRS 2 were similar with both types of insulin (Fig. 2 D) . There were no differences of the IGF-I receptor expression across the wide spectrum of insulin concentrations. IRS 2 expression was down-regulated at high concentrations of regular human insulin. Increasing insulin glargine concentrations did not induce changes in the expression levels of total IRS 2. Expression of the insulin receptor was down-regulated at high concentrations of insulin glargine as well as regular human insulin (Fig. 2 D) . However comparing both insulins the expression levels did not show a significant difference at any of the concentrations tested. Survival analysis. To extend the analysis of the long acting insulin analogue glargine into the clinical context of pancreatic cancer we examined the survival of patients after surgery due to pancreatic carcinoma. Subjects were analyzed over a median follow-up period of 22 month after surgery (total n=125). Strategies of insulin therapy were equally distributed among both groups with diabetic patients (Tab. 1). There were no differences regarding gender, age, tumor stage and histomorphology of the tumors between the subject groups. Similarly the surgical techniques and status of resection, which have an important impact on patients´ survival, did not differ in the three groups. The median survival time was 15 months (Fig. 3 A) . Survival analysis (Kaplan-Meier) showed that the time-dependent proportion of patients surviving was not altered by insulin glargine (p=0.4, 3-samplecomparison; Fig. 3 B) compared to treatment with regular human insulin and subjects after pancreatectomy without diabetes mellitus.
DISCUSSION
In the present study we sought to investigate the influence of insulin glargine on proliferation of pancreatic cancer cells in comparison to regular human insulin and whether treatment with insulin glargine has an impact on the survival of patients with pancreatic carcinoma. These questions were addressed using a human pancreatic cancer cell line for the in vitro studies and additionally analyzing patients after pancreatectomy due to pancreatic carcinoma. Short term incubation studies confirmed that the cells used in the present projects respond to exogenous insulin. We report that the turnover of human pancreatic cancer cells is not altered by insulin glargine. There were also no significant differences of the expression patterns of the insulin and IGF-I receptor compared to regular human insulin. Unchanged cell proliferation after prolonged incubation might be partially due to downregulation of the insulin receptor. With low (0.01-1nM) and high (10-100nM) insulin concentrations we reproduced physiological and supraphysiological conditions. This was necessary because insulin selectively activates the insulin receptor at physiological concentrations whereas at high concentrations it cross-activates the IGF-I receptor (8) . Survival after surgery because of pancreatic carcinoma was not influenced by the type of insulin used for therapy of diabetes mellitus. Prior receptor-binding studies using different types of insulin demonstrated that structural modifications of the insulin molecule at its C-terminus are responsible for an altered affinity to the IGF-I receptor (12) . Accordingly an about 6-fold higher affinity of insulin glargine to the IGF-I receptor was observed (7) . It was hypothesized that mitogenic effects of insulin are mainly mediated through IGF-I receptor stimulation at high insulin concentrations. In an experimental model the proliferation of human osteosarcoma cells directly correlated with the increased affinity of insulin glargine to the IGF-I receptor (7) . From these studies it was inferred that treatment with insulin glargine might induce cell proliferation in various tissues. However an increased mitogenic potential has not been supported in other studies. In comparison to regular human insulin the proliferation of insulin glargine treated cells was not significantly different in human coronary artery endothelial and smooth muscle cells (13) , skeletal muscle cells (14) , rat fibroblasts (15), cardiac myoblasts and adult rat ventricular cardiomyocytes (16) . One in vivo study in rats and mice reported no significant difference between insulin glargine and NPH-insulin regarding the development of mammary tumors (17) . In the present study, we extended the experimental evidence into the context of pancreatic cancer and report that insulin glargine does not induce proliferation of pancreatic cancer cells compared to regular human insulin. It is established that the development of pancreatic cancer is associated with diabetes mellitus. However an exact mechanism has not been identified. On the one hand type 2 diabetes mellitus is considered a risk factor for several types of cancer, e.g. of the pancreas (18), breast (19) , endometrium (20) , liver (21), bladder (22) , colon and rectum (23) (24) (25) . Therefore it was postulated that the increased risk is mainly constituted by elevated concentrations of circulating insulin (26) compared to insulin levels in lean non-diabetic humans. On the other hand there is also evidence from casecontrol studies to suggest that pancreatic cancer triggers the development of diabetes mellitus, because there is a significant association between the two conditions if diabetes mellitus is diagnosed concomitantly or within two years before the diagnosis of cancer (27) . These studies allow the conclusion that glucose metabolism might be influenced by the tumor itself or a secreted product from the tumor with effects on insulin sensitivity (28) . Consistent with this hypothesis it has been reported that insulin sensitivity may be improving after resection of pancreatic tumors (29) . Pancreatic ductal adenocarcinoma, which is the most common form of pancreatic cancer in general and in our group of patients, is believed to originate from pancreatic progenitor or stem cells (30; 31) and not from pancreatic betacells (32) , which are exposed to the highest local insulin concentrations. When pancreatic progenitor or stem cells can be readily identified and are available for experimental applications it would be interesting to analyze the concentrationdependent effects of insulin in these cells with respect to tumor formation. Clinically this would be relevant for patients with diabetes mellitus prior to development of pancreatic cancer. The present result that survival of patients with pancreatic carcinoma is not influenced by diabetes mellitus is consistent with other reports showing that survival in patients with pancreatic carcinoma and a palliative therapeutic concept (33) or after surgical resection is not associated with the metabolic status (34) . However, median survival is short in the present group of patients. Therefore it might be interesting to perform similar analyses with patients undergoing surgery at earlier tumor stages than T3 and with longer survival. In summary, we demonstrated that regular human insulin as well as insulin glargine did not influence proliferation and apoptosis in human pancreatic cancer cells. Moreover therapy with both insulins was not associated with altered survival of patients after pancreatectomy due to pancreatic carcinoma. Based on these results regular human insulin and insulin glargine may be safely used to treat patients with pancreatic cancer and diabetes mellitus.
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